舒肝解郁胶囊治疗帕金森病合并抑郁的临床观察  

Clinical research on Shugan-jieyu capsule in the treatment of Parkinson's disease combined with depression

作　　者：刘红[1] 王玉芬[1] 崔艳艳[1] 

机构地区：[1]长治医学院附属和平医院神经内科,长治046000

出　　处：《世界临床药物》2015年第7期480-483,共4页World Clinical Drug

摘　　要：目的评价舒肝解郁胶囊治疗帕金森病(PD)合并抑郁的疗效及安全性。方法随机将70例帕金森病合并抑郁患者分成治疗组(舒肝解郁胶囊,n=36)及对照组(舍曲林,n=34),记录治疗前及治疗2、4、8和12周两组汉密顿抑郁量表(HAMD)及帕金森病综合评价量表(UPDRS)评分,并观察与用药相关的不良反应。结果治疗12周,治疗组总有效率达83.33%,与对照组(85.29%)相比,差异无统计学意义(P>0.05)。治疗组HAMD评分及UPDRSⅡ、UPDRSⅢ评分较治疗前均降低(P<0.05)。与同一时点对照组相比,两组HAMD评分及UPDRSⅡ、UPDRSⅢ评分差异无统计学意义(P>0.05)。结论对于PD合并抑郁患者的抑郁症状,舒肝解郁胶囊疗效与舍曲林相当,同时不加重PD患者的运动症状,不良反应少。Objective To investigate the efficacy and safety of Shugan-jieyu capsule in the treatment of Parkinson,sdisease （PD） combined with depression. Methods A total of 70 patients were randomly divided into treatment group（Shugan-jieyu capsule） and control group （sertraline）. Efficacy was measured by Hamilton Depression Scale （HAMD,17-item） and Unified Parkinson’s Disease Rating Scale （UPDRS） before and after treatments of 2, 4, 8 and 12 weeks.The adverse drug reactions related to medication was observed. Results After 12 weeks, compared with the control group（85.29%） the total effective rate of treatment group （83.33%） had no statistically significant difference （P 〉 0.05）.Compared with before treatment, the scores of HAMD and UPDRS Ⅱ and UPDRS Ⅲ in the treatment group weredecreased （P 〈 0.05）. Compared with the control group, there was no significant difference in HAMD, UPDRSⅡandUPDRS Ⅲ at the same time between two groups. Conclusion Shugan-jieyu capsule in the treatment of PD combined withdepression is safe and effective.

关 键 词：帕金森病(PD) 抑郁症 舒肝解郁胶囊 舍曲林 

分 类 号：R749.3[医药卫生—神经病学与精神病学] R741[医药卫生—临床医学]